Abbott Laboratories raised its 2024 earnings guidance after strong Q3 results, driven by growth in Pharma and MedTech ...

Johnson & Johnson’s medtech acquisitions over the past year have fueled growth for its cardiovascular group, offsetting ...

As medtech companies, experts and regulators gather in Toronto, FDA leadership changes and the upcoming U.S. presidential ...

JNJ's 3Q earnings expected to be $2.21 EPS and $22.16B revenue. Recent acquisitions and drug trials impacting stock's ...

Authors:Kirk Harmon, Vice President & GM, Contract Sales Organization, IQVIAJavier “Jave” Castillo, R.Ph, Vice President, CSO ...

Event puts focus on medical technologies Oct. 15-17 at the Metro Toronto Convention Centre ...

Focus on international early-stage and pre-commercial biotech & medtech opportunities ...

Employees at the 10 largest medtech employers in the world are excited about culture but are still frustrated by corporate ...

Our 2024 Women in Medtech edition features insights from Abbott's Lisa Earnhardt, Medtronic's Nina Goodheart, and more.

Johnson & Johnson beat investors’ expectations despite its medtech unit underperforming, with execs pointing to the Asia-Pacific region as a continued source of struggle. Executives said on the ...

Matt Miksic, an analyst from Barclays, maintained the Hold rating on Johnson & Johnson (JNJ – Research Report). The associated price ...